| Literature DB >> 30837243 |
Francesca R Auciello1,2, Vinay Bulusu1,2, Chet Oon3, Jacqueline Tait-Mulder1,2, Mark Berry3, Sohinee Bhattacharyya3, Sergey Tumanov1,2, Brittany L Allen-Petersen4, Jason Link4, Nicholas D Kendsersky4, Esmee Vringer1,2, Michelle Schug1,2, David Novo1, Rosa F Hwang5, Ronald M Evans6, Colin Nixon1, Craig Dorrell7, Jennifer P Morton1, Jim C Norman1, Rosalie C Sears4, Jurre J Kamphorst8,2, Mara H Sherman9.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) develops a pronounced stromal response reflecting an aberrant wound-healing process. This stromal reaction features transdifferentiation of tissue-resident pancreatic stellate cells (PSC) into activated cancer-associated fibroblasts, a process induced by PDAC cells but of unclear significance for PDAC progression. Here, we show that PSCs undergo a dramatic lipid metabolic shift during differentiation in the context of pancreatic tumorigenesis, including remodeling of the intracellular lipidome and secretion of abundant lipids in the activated, fibroblastic state. Specifically, stroma-derived lysophosphatidylcholines support PDAC cell synthesis of phosphatidylcholines, key components of cell membranes, and also facilitate production of the potent wound-healing mediator lysophosphatidic acid (LPA) by the extracellular enzyme autotaxin, which is overexpressed in PDAC. The autotaxin-LPA axis promotes PDAC cell proliferation, migration, and AKT activation, and genetic or pharmacologic autotaxin inhibition suppresses PDAC growth in vivo. Our work demonstrates how PDAC cells exploit the local production of wound-healing mediators to stimulate their own growth and migration. SIGNIFICANCE: Our work highlights an unanticipated role for PSCs in producing the oncogenic LPA signaling lipid and demonstrates how PDAC tumor cells co-opt the release of wound-healing mediators by neighboring PSCs to promote their own proliferation and migration.See related commentary by Biffi and Tuveson, p. 578.This article is highlighted in the In This Issue feature, p. 565. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30837243 PMCID: PMC6497553 DOI: 10.1158/2159-8290.CD-18-1212
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397